Oxidized cardiolipin as a pro-inflammatory factor
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/00
G01N-033/00
C07K-016/18
G01N-033/53
A61K-038/17
G01N-033/564
G01N-033/92
C07K-016/44
출원번호
US-0964581
(2013-08-12)
등록번호
US-10060908
(2018-08-28)
발명자
/ 주소
Frostegård, Johan
출원인 / 주소
MEDIRISTA BIOTECHNOLOGIES AB
대리인 / 주소
Parker Highlander PLLC
인용정보
피인용 횟수 :
0인용 특허 :
12
초록▼
Low levels of antibodies reactive with oxidized Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between man
Low levels of antibodies reactive with oxidized Cardiolipin (oxCL) in mammals are related to an increased risk of developing cardiovascular diseases, auto-immune diseases or inflammatory conditions. High levels can have a protective function and in general there is a negative association between manifestations of these conditions and antibodies against oxCL. Thus, based on their relations methods of monitoring, determining and diagnosing as well as methods of immunization and therapy of these diseases and conditions are provided.
대표청구항▼
1. A method of treating or reducing the risk of developing arthritis in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of Annexin A5, wherein the arthritis is osteoarthritis or psoriatic arthritis. 2. The method according to claim 1, wherein the a
1. A method of treating or reducing the risk of developing arthritis in a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of Annexin A5, wherein the arthritis is osteoarthritis or psoriatic arthritis. 2. The method according to claim 1, wherein the arthritis is osteoarthritis. 3. The method according to claim 2, wherein the mammal is selected from the group consisting of mice, rats, rabbits, dogs, cats, cattle, horses and humans. 4. The method according to claim 3, wherein the mammal is a horse. 5. The method according to claim 3, wherein the mammal is a dog. 6. The method according to claim 3, wherein the mammal is a human. 7. The method according to claim 2, wherein the Annexin A5 is in combination with any suitable adjuvants. 8. The method according to claim 1, wherein the arthritis is psoriatic arthritis. 9. The method according to claim 8, wherein the mammal is selected from the group consisting of mice, rats, rabbits, dogs, cats, cattle, horses and humans. 10. The method according to claim 9, wherein the mammal is a horse. 11. The method according to claim 9, wherein the mammal is a dog. 12. The method according to claim 9, wherein the mammal is a human. 13. The method according to claim 8, wherein the Annexin A5 is in combination with any suitable adjuvants. 14. The method according to claim 1, wherein the mammal is selected from the group consisting of mice, rats, rabbits, dogs, cats, cattle, horses and humans. 15. The method according to claim 14, wherein the mammal is a horse. 16. The method according to claim 14, wherein the mammal is a dog. 17. The method according to claim 14, wherein the mammal is a human. 18. The method according to claim 1, wherein the Annexin A5 is in combination with any suitable adjuvants.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (12)
Morrow J. Thomas (Beaverton OR) Covey Eugene C. (Portland OR), Hypodermic injection apparatus.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.